» Articles » PMID: 35600859

Evidence and Characteristics of Traditional Chinese Medicine for Coronary Heart Disease Patients With Anxiety or Depression: A Meta-Analysis and Systematic Review

Overview
Journal Front Pharmacol
Date 2022 May 23
PMID 35600859
Authors
Affiliations
Soon will be listed here.
Abstract

The objective of this study was to assess the efficacy and potential mechanisms of Chinese herbal medicine (CHM) for treating coronary heart disease (CHD) patients with anxiety or depression. A systematic literature search was performed. Screening studies, extracting data, and assessing article quality were carried out independently by two researchers. The active ingredients of CHM for the treatment of CHD with anxiety or depression were analyzed by the network pharmacology, and the main potential mechanisms were summarized by the database of Web of Science. A total of 32 studies were included. The results showed that compared with the blank control groups, CHM was more beneficial in treating anxiety or depression in patients with CHD [anxiety: OR = 3.22, 95% CI (1.94, 5.35), < 0.00001, I = 0%; depression: OR = 3.27, 95% CI (1.67, 6.40), = 0.0005, I = 0%], and the efficacy of CHM was not inferior to that of Western medicine (WM) [anxiety: OR = 1.58, 95%CI (0.39, 6.35), = 0.52, I = 67%; depression: OR = 1.97, 95%CI (0.73, 5.28), = 0.18, I = 33%,]. Additionally, CHM also showed a significant advantage in improving angina stability (AS) in CHD patients with anxiety or depression compared with blank groups [anxiety: SMD = 0.55, 95%CI (0.32, 0.79), < 0.00001, I = 0%; depression: = 0.004] and WM groups [anxiety: SMD = 1.14, 95%CI (0.80, 1.47), < 0.00001, I = 0%; depression: SMD = 12.15, 95%CI (6.07, 18.23), < 0.0001, I = 0%]. Angina frequency (AF) and electrocardiogram (ECG) analysis after using CHM demonstrated similar trends. Based on the network pharmacology, quercetin, kaempferol, luteolin, beta-sitosterol, puerarin, stigmasterol, isorhamnetin, baicalein, tanshinone IIa, and nobiletin were most closely and simultaneously related to the pathological targets of CHD, anxiety, and depression. The main underlying mechanisms might involve anti-damage/apoptosis, anti-inflammation, antioxidative stress, and maintaining neurotransmitter homeostasis. CHM exhibited an obvious efficacy in treating CHD patients with anxiety or depression, especially for improving the symptom of angina pectoris. The most active compounds of CHM could simultaneously act on the pathological targets of CHD, anxiety, and depression. Multiple effective components and multiple targets were the advantages of CHM compared with WM.

Citing Articles

Therapeutic mechanism and key active ingredients of Yinxing Mihuan Oral Solution in coronary heart disease comorbidity with anxiety: A network pharmacology and molecular docking approach.

Jin J, Chen H, Wang H, Gu Y, Yang L Medicine (Baltimore). 2024; 103(43):e40183.

PMID: 39470548 PMC: 11521018. DOI: 10.1097/MD.0000000000040183.


Omega-3 PUFAs' efficacy in the therapy of coronary artery disease combined with anxiety or depression: a meta-analysis.

Gui Y, He D, Li J, Zhao H Front Psychiatry. 2024; 15:1368007.

PMID: 38979505 PMC: 11228296. DOI: 10.3389/fpsyt.2024.1368007.


Uncovering the molecular mechanism of Mume Fructus in treatment of Sjögren's syndrome.

Sun Z, Deng L, Xu Z, Yang K, Yu P Medicine (Baltimore). 2024; 103(19):e38085.

PMID: 38728503 PMC: 11081559. DOI: 10.1097/MD.0000000000038085.


Depression and coronary heart disease: mechanisms, interventions, and treatments.

Xu L, Zhai X, Shi D, Zhang Y Front Psychiatry. 2024; 15:1328048.

PMID: 38404466 PMC: 10884284. DOI: 10.3389/fpsyt.2024.1328048.


Real-world observations and impacts of Chinese herbal medicine for migraine: results of a registry-based cohort study.

Lyu S, Zhang C, Zhang A, Guo X, Hua R, Mao Z Front Pharmacol. 2024; 15:1330589.

PMID: 38370478 PMC: 10874640. DOI: 10.3389/fphar.2024.1330589.

References
1.
Lu J, Zhou H, Meng D, Zhang J, Pan K, Wan B . Tanshinone IIA Improves Depression-like Behavior in Mice by Activating the ERK-CREB-BDNF Signaling Pathway. Neuroscience. 2020; 430:1-11. DOI: 10.1016/j.neuroscience.2020.01.026. View

2.
Coleta M, Campos M, Cotrim M, de Lima T, Cunha A . Assessment of luteolin (3',4',5,7-tetrahydroxyflavone) neuropharmacological activity. Behav Brain Res. 2008; 189(1):75-82. DOI: 10.1016/j.bbr.2007.12.010. View

3.
Zhang B, Jiang H, Chen J, Guo X, Li Y, Hu Q . Nobiletin ameliorates myocardial ischemia and reperfusion injury by attenuating endoplasmic reticulum stress-associated apoptosis through regulation of the PI3K/AKT signal pathway. Int Immunopharmacol. 2019; 73:98-107. DOI: 10.1016/j.intimp.2019.04.060. View

4.
Song L, Yang H, Wang H, Tian C, Liu Y, Zeng X . Inhibition of 12/15 lipoxygenase by baicalein reduces myocardial ischemia/reperfusion injury via modulation of multiple signaling pathways. Apoptosis. 2013; 19(4):567-80. DOI: 10.1007/s10495-013-0946-z. View

5.
Jie Z, Xiujian W, Jin L . Pharmacological mechanism and apoptosis effect of baicalein in protecting myocardial ischemia reperfusion injury in rats. Pak J Pharm Sci. 2019; 32(1(Special)):407-412. View